VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development of BET inhibitors in large inflammation and immunology, or I&I, opportunities, notes the analyst, who adds that the class has well-understood relevance in oncology, but its potential in I&I is “a more recent revelation largely owed to efforts” by VYNE. The company’s lead program, VYN201, is a topical BET inhibitor that the firm sees having high odds of emerging as the next first-line targeted therapy for non-segmental vitiligo, which it calls a market with “high growth potential.”